Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis
Launched by MARCO CAPOGROSSO ·
Trial Information
Current as of September 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help adults who have weakness or partial paralysis in their arm and hand after a stroke. Researchers are testing if combining spinal cord stimulation—a treatment where small electrical signals are sent to the spinal cord—with regular physical therapy can improve arm and hand movement better than therapy alone. The study involves three parts: first, participants will do physical therapy for six weeks; next, they will receive a small device implanted near their spinal cord and continue the same physical therapy while using this stimulation; finally, they will stop using the device at home but return to the clinic monthly for up to six months to check how well their arm and hand are working.
Adults who have had a stroke and have weakness on one side of their body in the upper limb may be eligible to join. Participants should be willing to commit to regular therapy sessions and follow-up visits. It’s important to know that the stimulation device is only used during therapy sessions, not at home. This study is not yet recruiting, but it offers a promising option for people looking to improve arm and hand function after a stroke through a combination of cutting-edge technology and physical training.
Gender
ALL
Eligibility criteria
About Marco Capogrosso
Marco Capogrosso is a distinguished clinical trial sponsor with expertise in advancing medical research and innovation. With a robust background in clinical development, Capogrosso is dedicated to facilitating the progression of novel therapies through well-designed and rigorously conducted clinical trials. His commitment to ethical standards and patient safety ensures that each study is conducted with the utmost integrity, while his collaborative approach fosters strong partnerships with research institutions, regulatory bodies, and healthcare professionals. By leveraging cutting-edge methodologies and a patient-centered focus, Marco Capogrosso aims to contribute significantly to the advancement of healthcare solutions that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
George Wittenberg, MD, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported